Intra-Cellular Therapies Presents Additional Efficacy and Safety Data From the Positive Phase 3 Clinical Trial of ITI-007

News
1

http://finance.yahoo.com/news/intra-cellular-therapies-presents-additional-210100908.html

Poster W166 entitled “Clinical Development of ITI-007 for the Treatment of Schizophrenia” described additional data from the ITI-007-301 trial, topline results of which were announced in September 2015:

ITI-007 60 mg improved symptoms of schizophrenia and met the primary endpoint demonstrating statistically significant superiority over placebo at Day 28 as measured by the Positive and Negative Syndrome Scale (PANSS) total score. The 40 mg dose approximated the trajectory of improvement seen with the 60 mg dose, but the effect with 40 mg did not reach statistical significance on the PANSS total score.

Both the 60 mg and 40 mg doses of ITI-007 significantly reduced the PANSS positive symptom subscale score versus placebo at study endpoint and at earlier time points.

6 Likes
2

Sounds really promising!

3

good news…
a hope for szian… :fireworks:

4

It’s fitting that James Bond delivered the news of the new ITI-007 drug.

2 Likes
5

Excellent news. This is what everyone will be on in the future (if their insurance covers it).

6

hope it won’t cause any sexual dysfunction … :pray:

1 Like
7

This drug sounds really promissing. Looking forward to it.

8

Im a little leary trying new drugs, especially AP’s.

I dont know if I would take the chance of getting off a stabilizing med for me like Risperdal, just to get on a brand new med thats basically not been proven.

Too many risks involved.